United StatesA bipartisan group of U.S. Congress members has written to the Department of Health and Human Services, requesting that Eli Lilly be compelled to resume providing discounted drug prices to participating hospitals under the 340B program. The pharmaceutical company ceased these discounts in June 2026, citing concerns over 'duplicate discounts' and stating that many hospitals had not shared required claims data. Lilly reportedly targeted 50 large hospital systems out of around 1,000 that had not adhered to a new policy implemented earlier in the year. The company claimed that over 70% of the 2,300+ hospitals in the program had already submitted the necessary information.
Bias read (Center): The article presents both perspectives—lawmakers arguing that Eli Lilly is violating federal law by discontinuing discounts, and Lilly explaining its decision based on compliance with a new policy. No overtly biased language or selective sourcing is evident, and the framing remains neutral, focusing
